Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
AstraZeneca
Dow
Colorcon
Merck

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for GS-4997

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug GS-4997: Patents, clinical trial progress, indications

GS-4997 is an investigational drug.

There have been 9 clinical trials for GS-4997. The most recent clinical trial was a Phase 2 trial, which was initiated on January 30th 2017.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Kidney Diseases. The leading clinical trial sponsors are Gilead Sciences, HepQuant, LLC, and [disabled in preview].

There are eleven US patents protecting this investigational drug and one hundred and sixty-five international patents.

Recent Clinical Trials for GS-4997
TitleSponsorPhase
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) FibrosisGilead SciencesPhase 3
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)Gilead SciencesPhase 3
GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)Gilead SciencesPhase 2

See all GS-4997 clinical trials

Clinical Trial Summary for GS-4997

Top disease conditions for GS-4997
Top clinical trial sponsors for GS-4997

See all GS-4997 clinical trials

US Patents for GS-4997

Glossary
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-4997   Start Trial Methods of treating liver disease Gilead Sciences, Inc. (Foster City, CA)   Start Trial
GS-4997   Start Trial Apoptosis signal-regulating kinase inhibitors Gilead Sciences, Inc. (Foster City, CA)   Start Trial
GS-4997   Start Trial Apoptosis signal-regulating kinase inhibitor Gilead Sciences, Inc. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
AstraZeneca
Mallinckrodt
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
 NCE-1 Generic Application Dates 2019 - 2020
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews